AI Article Synopsis

  • - The study evaluated the effectiveness and safety of adding adjuvant S-1 chemotherapy after surgery in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who previously received neoadjuvant chemotherapy followed by surgery (NAC-S).
  • - A total of 52 patients participated, with a reported 3-year relapse-free survival rate of 72.3% and overall survival rate of 85.0%, indicating successful outcomes for the primary endpoint.
  • - The treatment had some side effects, with the most common grade ≥3 adverse events being neutropenia, anorexia, and diarrhea; however, no treatment-related deaths occurred, suggesting it is a safe option worth exploring further.

Article Abstract

Background: Neoadjuvant chemotherapy followed by surgery (NAC-S) is the standard therapy for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan.

Objective: The aim of this phase II trial was to assess the efficacy and safety of the addition of adjuvant S-1 after R0 resection in ESCC patients who received NAC-S.

Patients And Methods: Key eligibility criteria included clinical stage IB-III (without T4 disease) ESCC, age 20-75 years, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients received adjuvant therapy with four cycles of S-1 (80 mg/m/day) administered orally for 4 weeks of 6-week cycles. The primary endpoint was 3 year relapse-free survival (RFS). If the lower confidence limit for 3 year RFS was >50%, we judged that the primary endpoint of this study was met.

Results: A total of 52 patients were enrolled between January 2016 and January 2019. Two patients were excluded from analysis; five patients were determined to have R1 or R2 resection, and seven patients did not receive adjuvant S-1. The 3-year RFS and overall survival rates in the intention-to-treat population were 72.3% (90% confidence interval [CI] 59.9-81.5) and 85.0% (90% CI 73.9-91.6), indicating that the primary endpoint was met. Grade ≥3 adverse events with an incidence ≥10% included neutropenia (13.2%), anorexia (13.2%), and diarrhea (10.5%). There were no treatment-related deaths.

Conclusion: Adjuvant S-1 after NAC-S showed promising efficacy with a manageable safety profile for patients with resectable ESCC and warrants further evaluation in larger studies.

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-024-16325-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659372PMC

Publication Analysis

Top Keywords

adjuvant s-1
16
primary endpoint
12
phase trial
8
neoadjuvant chemotherapy
8
chemotherapy surgery
8
patients
8
locally advanced
8
advanced esophageal
8
esophageal squamous
8
squamous cell
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!